Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue growth ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has completed its $3.9 billion acquisition of Stamford-based SpringWorks Therapeutics ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA is still scouting for acquisition targets after the German drug-to-semiconductor group completed its $3.9 billion takeover of SpringWorks Therapeutics Inc. on Tuesday.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...